Cora NelsonSerena Williams arrived at the 2026 Met Gala on May 4 in a metallic Marc Jacobs gown — but the story generating the most conversation was not her outfit. Weeks before the event, the retired tennis legend disclosed publicly that she used a GLP-1 medication through healthcare company Ro to lose 31 pounds following the birth of her second daughter. Williams said she had never "been in a place like that in my life where I worked so hard, ate so healthy and could never get down to where I needed to be." Her experience has reignited a critical conversation about postpartum health, weight loss medication, and when women should seek a specialist's guidance.
A Year of Postpartum Struggle — Then GLP-1
Williams gave birth to her daughter Adira in 2023. By her account, months of disciplined exercise and clean eating produced no meaningful weight change. After starting GLP-1 therapy, she lost 31 pounds and reported secondary benefits including reduced joint pain and improved mobility. She now serves as a brand ambassador for Ro.
GLP-1 receptor agonists — including semaglutide (sold under brand names Wegovy and Ozempic) and tirzepatide (Zepbound) — work by mimicking a hormone that regulates appetite and slows gastric emptying. Originally developed for Type 2 diabetes management, the medications received FDA approvals for chronic weight management in adults with obesity or weight-related conditions. According to the CDC's maternal health data, postpartum weight retention affects a significant proportion of women and is associated with longer-term metabolic risks.
Serena's Postpartum History: Why Her Story Matters for Women's Health
Williams nearly died following the delivery of her first daughter Olympia in 2017. A pulmonary embolism — a blood clot in the lungs — required emergency surgery. Williams later described how medical staff initially dismissed her concerns, and she has since become one of the most prominent voices on Black maternal health disparities in the United States.
That history is directly relevant to GLP-1 conversations. Women with a prior history of blood clots, cardiovascular events, or pregnancy complications require personalized medical evaluation before starting weight loss medications. GLP-1 drugs are not universally safe for postpartum patients, and the timing of medication relative to breastfeeding, hormonal changes, and recovery status matters significantly.
"Serena's disclosure is helpful because it opens the door for women to have conversations they were afraid to start," says a physician specializing in women's metabolic health. "But her experience is not a template. A woman's postpartum health profile, clotting history, and medications need to be reviewed before any GLP-1 prescription."
Four Questions to Ask Your Doctor Before Starting GLP-1
If Serena's story has you considering GLP-1 therapy, these are the four questions a specialist recommends every woman ask:
1. Am I clinically eligible? FDA-approved GLP-1 medications for weight loss are indicated for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. Eligibility is not based on aesthetic goals alone. A physician must assess your full health profile.
2. Is my postpartum timeline appropriate? Most guidelines recommend against starting new weight loss medications while breastfeeding, and suggest waiting until hormonal levels have stabilized — typically at least 12 weeks postpartum. Some studies suggest longer waiting periods for women with surgical deliveries.
3. What are the contraindications for my specific history? GLP-1 medications carry contraindications including personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and certain pancreatitis histories. For women with prior cardiovascular events — including clotting disorders — cardiovascular monitoring may be required.
4. How will I access ongoing supervision? Telehealth platforms like Ro, Hims & Hers, and others now offer GLP-1 prescriptions online with minimal in-person contact. The convenience is real, but so is the tradeoff: ongoing monitoring of side effects, nutritional deficiencies, and metabolic markers requires a clinical relationship. Ask specifically how your prescriber will track your health over time.
For more on the broader GLP-1 approval landscape, see what the FDA approval of Wegovy HD means for patients and their doctors.
When to Consult a Specialist vs. a Telehealth Provider
Not all GLP-1 prescriptions carry the same level of clinical oversight. A telehealth prescription may be appropriate for a healthy adult with straightforward eligibility. But if you have a complex postpartum history — prior clotting events, hypertensive disorders of pregnancy, gestational diabetes, or a C-section delivery — an in-person consultation with an endocrinologist, OB-GYN, or internal medicine physician is strongly recommended before starting medication.
Williams' story is a reminder that postpartum health is not a single moment — it is a multi-year continuum. Her near-death experience in 2017 and her 2026 metabolic health journey are two points on the same timeline. For women navigating that timeline, professional guidance is not a luxury. It is a safeguard. Read how another high-profile athlete used GLP-1 safely and what their medical team recommended.
The Bottom Line
Serena Williams used a GLP-1 medication to manage postpartum weight after conventional approaches stopped working. Her disclosure is clinically significant — not because GLP-1 therapy is right for everyone, but because it normalizes women seeking medical support for a real and documented health challenge. The key is finding the right professional to guide that journey safely.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any new medication or treatment.
